Trial Profile
A Study to Evaluate the Pembrolizumab and Nivolumab Associated Adverse Events in Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 25 Apr 2016 New trial record
- 12 Apr 2016 Results published in the European Journal of Cancer